Advances PBH Development Program Following August 2026 Initial Public OfferingStrengthens Balance Sheet with $82.1 Million in Total Cash, Cash Equivalents, and Marketable Securities
RALEIGH, NC / ACCESS Newswire /
Randomized, double-blind, placebo-controlled trial will evaluate two doses of the first-in-class, minimally absorbed SGLT1 inhibitor in patients with recurrent hypoglycemia following bariatric surgery
RALEIGH, NC
Thirty-year biopharmaceutical commercial leader transitions from the Board of Directors to Chief Commercial OfficerAppointment strengthens corporate strategy, business development and commercial readiness as the Company
Former Chief Executive Officer of PA Consulting brings three decades of global professional services and life sciences leadership experienceAppointment broadens independent oversight as the Company scales operations
LOS ANGELES and NEW YORK, Aug. 17, 2026 /PRNewswire/ -- JonesTrading Institutional Services LLC ("Jones") today announced that it served as sole book-running manager for the $81.3 million initial public offering
RALEIGH, NC / ACCESS Newswire / August 13, 2026 / Vogenx, Inc. (NASDAQ:VOGX) ("Vogenx"), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the
RALEIGH, NC / ACCESS Newswire / August 11, 2026 / Vogenx, Inc. (NASDAQ:VOGX) ("Vogenx"), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the
